Personal Genome Diagnostics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
200
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$575M
Personal Genome Diagnostics General Information
Description
Developer of cancer genome testing products designed to empower the fight against cancer by unlocking actionable information from the genome. The company's technologies and bioinformatics help in identifying tumor mutations with accuracy by identifying alterations in complex cancer genomes, enabling oncology researchers, drug developers, clinicians, and patients to address cancer-related genetic changes.
Contact Information
Website
www.personalgenome.com(Operating Subsidiary)
Corporate Office
- 3600 Boston Street
- Suite 10
- Baltimore, MD 21224
- United States
Corporate Office
- 3600 Boston Street
- Suite 10
- Baltimore, MD 21224
- United States
Personal Genome Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 18-Feb-2022 | $575M | Completed | Generating Revenue | ||
| 13. Later Stage VC (Series C) | 10-Feb-2021 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series 1) | 24-Jul-2020 | Completed | Generating Revenue | |||
| 11. Debt - PPP | 27-Apr-2020 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series B) | 04-Jan-2018 | Completed | Generating Revenue | |||
| 9. Debt - General | 05-Jan-2016 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 28-Oct-2015 | Completed | Generating Revenue | |||
| 7. Debt - General | 27-Jul-2015 | Completed | Generating Revenue | |||
| 6. Seed Round | 02-Apr-2014 | $2.8M | $3.3M | Completed | Startup | |
| 5. Accelerator/Incubator | $500K | Completed | Startup |
Personal Genome Diagnostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series 1 | ||||||||
| Series B | 17,648,295 | $0.001000 | $3.13 | $3.13 | 1x | $3.13 | 2.07% | |
| Series A | 14,322,061 | $0.001000 | $1.48 | $1.48 | 1x | $1.48 | 1.68% |
Personal Genome Diagnostics Comparisons
Industry
Financing
Details
Personal Genome Diagnostics Competitors (38)
One of Personal Genome Diagnostics’s 38 competitors is Caris Life Sciences, a Private Equity-Backed company based in Irving, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caris Life Sciences | Private Equity-Backed | Irving, TX | ||||
| NuProbe | Venture Capital-Backed | Houston, TX | ||||
| Recombinetics | Venture Capital-Backed | Eagan, MN | ||||
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT |
Personal Genome Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Personal Genome Diagnostics Patents
Personal Genome Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240363245-A1 | Cancer detection through integrated analysis of whole genome sequencing | Pending | 17-Apr-2023 | ||
| US-20220356513-A1 | Synthetic polynucleotides and method of use thereof in genetic analysis | Pending | 07-May-2021 | ||
| AU-2022270021-A1 | Synthetic polynucleotides and method of use thereof in genetic analysis | Pending | 07-May-2021 | ||
| CA-3216028-A1 | Synthetic polynucleotides and method of use thereof in genetic analysis | Pending | 07-May-2021 | ||
| GB-2622165-A | Synthetic polynucleotides and method of use thereof in genetic analysis | Pending | 07-May-2021 | C12Q1/6883 |
Personal Genome Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Personal Genome Diagnostics Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3B Future Health Fund | Venture Capital | Minority | ||
| Abell Foundation | Not-For-Profit Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Co-Win Ventures | Venture Capital | Minority |
Personal Genome Diagnostics FAQs
-
When was Personal Genome Diagnostics founded?
Personal Genome Diagnostics was founded in 2010.
-
Where is Personal Genome Diagnostics headquartered?
Personal Genome Diagnostics is headquartered in Baltimore, MD.
-
What is the size of Personal Genome Diagnostics?
Personal Genome Diagnostics has 200 total employees.
-
What industry is Personal Genome Diagnostics in?
Personal Genome Diagnostics’s primary industry is Biotechnology.
-
Is Personal Genome Diagnostics a private or public company?
Personal Genome Diagnostics is a Private company.
-
What is the current valuation of Personal Genome Diagnostics?
The current valuation of Personal Genome Diagnostics is .
-
What is Personal Genome Diagnostics’s current revenue?
The current revenue for Personal Genome Diagnostics is .
-
How much funding has Personal Genome Diagnostics raised over time?
Personal Genome Diagnostics has raised $210M.
-
Who are Personal Genome Diagnostics’s investors?
3B Future Health Fund, Abell Foundation, Bristol-Myers Squibb, Catalio Capital Management, and Co-Win Ventures are 5 of 22 investors who have invested in Personal Genome Diagnostics.
-
Who are Personal Genome Diagnostics’s competitors?
Caris Life Sciences, NuProbe, Recombinetics, Deep Genomics, and Myriad Genetics are some of the 38 competitors of Personal Genome Diagnostics.
-
When was Personal Genome Diagnostics acquired?
Personal Genome Diagnostics was acquired on 18-Feb-2022.
-
Who acquired Personal Genome Diagnostics?
Personal Genome Diagnostics was acquired by Laboratory Corporation of America.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
